Nasdaq · Biotech stocks database
GRFS — Grifols S.A. ☆
GRFS (Grifols S.A.) stock: $8.43, $5.80B market cap, $1.02B cash, $5.15B EV, $5.80B fully diluted market cap. Data from Fully Diluted's biotech stocks database.
Overview
Catalysts
Assets
Pipeline
Trials
Holders
News
What they do
We are one of the leading global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value.
Source: 20-F FY2025 via SEC EDGAR
Enterprise value
$5,149.6M
Balance sheet
Cash $1,017.9M Debt $371.4M Net cash $646.5M Enterprise value $5,149.6M Basic shares 687.5M shares Fully diluted shares 687.6M shares Fully diluted market cap $5,796.1M Cash per share $1.48
Cash figures as of 2024-12-31. Database snapshot: 2026-11-07.
Share structure
Cap table as of 2025-12-31.
Price history Loading GRFS daily closes…
Loading price history…
Next catalyst Albumin infusion (25% albumin) · Jan 12 - Feb 23 in 9 wks · Phase 2 · Cirrhosis; Ascites HepaticAll upcoming catalysts (+6 more) →
Upcoming catalysts Expected Drug Phase Indication Mgmt guide Jan 12 - Feb 23 in 9 wks Albumin infusion (25% albumin) Phase 2 Cirrhosis; Ascites Hepatic — Nov 11 - Dec 23 in 12 mo Alpha-1 15% Phase 3 Alpha 1 Antitrypsin Deficiency — Feb 11 - Mar 24 in 15 mo Gamunex-C Phase 3 CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy) — Oct 12 - Nov 23 in 24 mo Gamunex-C, 10% Injectable Solution Phase 3 Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphom — Oct 13 - Nov 24 in 24 mo Alpha-1 MP Phase 3 Pulmonary Emphysema in Alpha-1 Antitrypsin Deficiency — Jan 12 - Feb 23 in 27 mo Plasma-derived AT-III concentrate Phase 3 Antithrombin III Deficiency — Sep 12 - Oct 24 in 35 mo Xembify Phase 3 Hypogammaglobulinemia; Bacterial Infections; B-cell Chronic Lymphocytic Leukemia —
Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Full readout calendar →
Asset data not yet available for this company.
No lead program on file for this company.
Active clinical trials Trial Phase Status Role Sponsor BP Condition(s) Mgmt guide NCT07555483 Phase 3 Recruiting Sponsor GRFS — Alpha 1 Antitrypsin Deficiency — NCT07540221 Phase 3 Recruiting Sponsor GRFS — CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy) — NCT07582432 Phase 3 Recruiting Sponsor GRFS — Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphom — NCT02796937 Phase 3 Enrolling by invitation Sponsor GRFS — Pulmonary Emphysema in Alpha-1 Antitrypsin Deficiency — NCT00319228 Phase 3 Active, not recruiting Sponsor GRFS — Antithrombin III Deficiency — NCT05645107 Phase 3 Recruiting Sponsor GRFS — Hypogammaglobulinemia; Bacterial Infections; B-cell Chronic Lymphocytic Leukemia — NCT01983241 Phase 3 Active, not recruiting Sponsor GRFS — Pulmonary Emphysema in Alpha-1 PI Deficiency — NCT00555555 Not disclosed Active, not recruiting Sponsor GRFS — Von Willebrand Disease — NCT06052176 Phase 2 Active, not recruiting Collaborator Hunter Holmes Mcguire Veteran Affairs Medical Center — Cirrhosis; Hepatic Encephalopathy — NCT05794165 Phase 2 Enrolling by invitation Collaborator Bryan Cotton — Trauma Injury; Thromboembolism; Venous Thromboembolism — NCT06812390 Phase 2 Recruiting Collaborator Anahita Rabiee MD MHS — Cirrhosis; Ascites Hepatic — NCT07152834 Not disclosed Recruiting Collaborator Muğla Sıtkı Koçman University — Alpha 1-antitrypsin Deficiency (AATD) —
Sponsor-matched active trials from ClinicalTrials.gov (8 as sponsor, 5 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.
View all 13 active trials for Grifols Therapeutics LLC on ClinicalTrials.gov
Specialist fund holders Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.
None of the tracked specialist funds reported a position in the latest 13F snapshot.
Fully Diluted · Free biotech stocks database. Figures are sourced from SEC filings and company disclosures; not investment advice.